...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and applied thrombosis/hemostasis : >Effect of Argatroban Combined With Dual Antiplatelet Therapy on Early Neurological Deterioration in Acute Minor Posterior Circulation Ischemic Stroke
【24h】

Effect of Argatroban Combined With Dual Antiplatelet Therapy on Early Neurological Deterioration in Acute Minor Posterior Circulation Ischemic Stroke

机译：ArgaTroban结合双抗血小板治疗对急性小循环缺血性卒中早期神经劣化的影响

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

There is a lack of studies on anticoagulant plus antiplatelet therapy for acute ischemic stroke. The present study made a pilot effort to investigate the efficacy and safety of argatroban plus dual antiplatelet therapy (DAPT) in patients with acute posterior circulation ischemic stroke (PCIS). We retrospectively collected patients diagnosed with acute PCIS according to inclusion/exclusion criteria. According to treatment drugs, patients were divided into an argatroban plus DAPT group and a DAPT group. The primary efficacy end point was the proportion of early neurological deterioration (END). The primary safety outcome was symptomatic intracranial hemorrhage. All outcomes were compared between the 2 groups before and after propensity score matching (PSM). A total of 502 patients were enrolled in the study, including 35 patients with argatroban plus DAPT and 467 patients with DAPT. There was a higher National Institutes of Health Stroke Scale (NIHSS) score in the argatroban plus DAPT group than the DAPT group before PSM (3 vs 2, P = .017). Compared with the DAPT group, the argatroban plus DAPT group had no END (before PSM: 0% vs 6.2%, P = .250; after PSM: 0% vs 5.9%, P = .298). Argatroban plus DAPT yielded a significant decrease in the NIHSS score from baseline to 7 days after hospitalization, compared with that of the DAPT group before PSM (P = .032), but not after PSM (P = .369). No symptomatic intracranial hemorrhage was found in any patient. A short-term combination of argatroban with DAPT appears safe in acute minor PCIS.
机译：患有急性缺血性卒中的抗凝血加抗血小板治疗缺乏研究。本研究制定了试验努力，以研究急性后循环缺血性脑卒中（PCIS）患者中Argatroban Plus双抗血小板治疗（DAPT）的疗效和安全性。我们回顾性地收集患者根据包含/排除标准诊断患有急性PCI的患者。根据治疗药物，患者分为Argatroban Plus DAPT组和DAPT组。主要疗效终点是早期神经劣化（终端）的比例。主要安全结果是对症颅内出血。在倾向分数匹配（PSM）之前和之后的2组之间比较所有结果。共有502名患者注册了该研究，其中35例Argatroban Plus DAPT和467名DAPT患者。在PSM之前的DAPT组（3 VS 2，P = .017）之前，在Argatroban Plus DAPT组中出现了更高的国家卫生冲程量表（NIHSS）分数。与DAPT组相比，Argatroban Plus DAPT组没有结束（PSM：0％VS 6.2％之前，P = .250; PSM：0％VS 5.9％，P = .298）。 Argatroban Plus DAPT在住院后，NIHSS评分的显着降低与PSM之前的DAPT组（P = .032）相比，但在PSM（P = .369）之后，与DAPT组（P = .369）相比。任何患者都没有发现任何症状的颅内出血。 Argatroban与DAPT的短期组合似乎在急性次要PCI中似乎安全。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号